Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
Go back to Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses| NORTHWEST BIO (AMEX: NWBO) | Delayed: 0.17 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.17 | 52 Week High | $5.19 | |||
| Open | $0.17 | 52 Week Low | $0.32 | |||
| Day High | $0.17 | P/E | N/A | |||
| Day Low | $0.17 | EPS | $-3.72 | |||
| Volume | 1,411,252 | |||||
